TORONTO, Canada (April 10, 2017) — PharmaCielo Ltd. is pleased to announce the appointment of Matteo Pellegrini to its Board of Directors. Mr. Pellegrini is a seasoned international business executive with 25 years of international management and leadership experience with Philip Morris International in numerous European and Asian countries.
He served from 2003 to 2015 as Philip Morris International’s President of Asia, where he spearheaded PMI’s expansion, completing three major acquisitions/mergers while leading the most innovative new product launch ever in the tobacco industry. He is well versed in marketing, sales, finance and M&A, and is noted for his ability to create highly effective teams.
Previously, Mr. Pellegrini led PMI divisions in four countries, as Managing Director of Philip Morris Italy, Phillip Morris France, Philip Morris Spain and Philip Morris Portugal. He was Marketing Director Italy, Business Development Manager for Philip Morris International, and began his tenure at PMI in 1991 as Brand Manager. “Mr. Pellegrini’s history of success in leading global businesses and business expansion continues to add international leadership strength to our Board of Directors,” said PharmaCielo Ltd. Chairman Simon Langelier. “His successful experience in helping to introduce new products and ways of thinking to a traditional industry in a variety of global markets is expected to translate equally well to helping PharmaCielo, as it similarly addresses the global marketplace.”
Mr. Pellegrini received his MBA, Advertising and Marketing Communication, from MasterPublitalia and his Bachelor’s in Business Administration from Università Bocconi, both in Milan, Italy. He resides in Hong Kong and speaks four languages in addition to his native Italian – English, French, Portuguese and Spanish.
About PharmaCielo Ltd.
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly-owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
This press release may contain forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.